Indaptus CEO reports 11.25M common shares stake

Indaptus Therapeutics Chief Executive Officer Junyi Dai reported ownership of 11,250,000 shares of common stock.

Rhea-AI Filing Summary

Indaptus Therapeutics Chief Executive Officer Junyi Dai reported ownership of 11,250,000 shares of common stock. This position reflects the full conversion of 75,000 shares of Series AAA Convertible Non-Redeemable Preferred Stock, which were acquired under a securities purchase agreement and then immediately converted after closing.

Insights

Equity ownership & governance analyst

CEO establishes a large direct equity stake via preferred stock conversion.

The filing shows Junyi Dai, CEO of Indaptus Therapeutics, holding 11,250,000 common shares following a conversion of preferred shares. The footnote explains that 75,000 Series AAA preferred shares were acquired and then fully converted into common stock.

This is an initial ownership report rather than a trade in the open market. It documents a significant direct equity position created through a structured transaction with a seller, David Elliot Lazar, and other purchasers. The filing does not compare this stake to total shares outstanding, so the overall ownership percentage is not indicated.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dai Junyi

Role Chief Executive Officer

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 11,250,000 shares (Direct)

Footnotes (1)

1. F1. On March 19, 2026, Junyi Dai (the "Reporting Person"), the other purchasers named therein and David Elliot Lazar (the "Seller") entered into a securities purchase agreement pursuant to which the Reporting Person acquired an aggregate of 75,000 shares of the Issuer's Series AAA Convertible Non-Redeemable Preferred Stock (the "Series AAA Preferred Stock"). Each share of Series AAA Preferred Stock is convertible into 150 shares of the Company's common stock, $0.01 par value per share (the "Common Stock"). Following the closing of such transaction which occurred on March 23, 2026, the Reporting Person submitted a notice of conversion with respect to all shares of Series AAA Preferred Stock held by the Reporting Person, resulting in the issuance of an aggregate of 11,250,000 shares of Common Stock.

Key Figures

Common shares held: 11,250,000 shares Preferred shares acquired: 75,000 shares Conversion ratio: 150 common shares per preferred share +1 more

4 metrics

Common shares held 11,250,000 shares Total common stock owned directly following reported transaction

Preferred shares acquired 75,000 shares Series AAA Convertible Non-Redeemable Preferred Stock acquired under purchase agreement

Conversion ratio 150 common shares per preferred share Each Series AAA preferred share convertible into common stock

Common shares issued on conversion 11,250,000 shares Aggregate common shares issued when all 75,000 preferred shares were converted

Key Terms

Series AAA Convertible Non-Redeemable Preferred Stock, securities purchase agreement, notice of conversion

3 terms

Series AAA Convertible Non-Redeemable Preferred Stock financial

"acquired an aggregate of 75,000 shares of the Issuer's Series AAA Convertible Non-Redeemable Preferred Stock"

A class of preferred shares that pays dividends and ranks ahead of common stock for dividends and asset claims, but does not obligate the issuer to buy them back (non-redeemable). They can be converted into common shares under specified terms, so they act like a hybrid between a bond and a stock; the "Series AAA" label simply identifies this particular issuance. Investors care because these features affect income, priority in a liquidation, and potential dilution if the shares convert to common stock.

securities purchase agreement financial

"entered into a securities purchase agreement pursuant to which the Reporting Person acquired"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

notice of conversion financial

"the Reporting Person submitted a notice of conversion with respect to all shares of Series AAA Preferred Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Indaptus Therapeutics (INDP) Form 3 for Junyi Dai report?

The Form 3 reports CEO Junyi Dai’s initial ownership of 11,250,000 Indaptus common shares. This stake comes from converting 75,000 shares of Series AAA Convertible Non-Redeemable Preferred Stock into common stock following a previously signed securities purchase agreement.

How did Indaptus CEO Junyi Dai obtain 11,250,000 INDP common shares?

Junyi Dai acquired 75,000 Series AAA preferred shares and then converted them into 11,250,000 common shares. The preferred stock was purchased under a securities purchase agreement and fully converted after the transaction closed, creating the reported common stock position.

What is the conversion rate of Indaptus Series AAA Convertible Non-Redeemable Preferred Stock?

Each share of Indaptus Series AAA preferred stock converts into 150 common shares. Based on this fixed conversion ratio, 75,000 preferred shares were converted into an aggregate of 11,250,000 shares of Indaptus Therapeutics common stock held by CEO Junyi Dai.

Who sold the Indaptus Series AAA preferred shares to CEO Junyi Dai?

The preferred shares were purchased from David Elliot Lazar as the identified seller. Junyi Dai and other purchasers entered into a securities purchase agreement with Lazar, acquiring 75,000 Series AAA preferred shares that were later fully converted into Indaptus common stock.

Does the Indaptus (INDP) Form 3 show any remaining preferred stock for Junyi Dai?

No remaining Series AAA preferred stock is indicated after the reported transaction. The footnote states that a notice of conversion was submitted for all 75,000 preferred shares, resulting in issuance of 11,250,000 common shares to the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 07:15 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dai Junyi

(Last) (First) (Middle)

C/O INDAPTUS THERAPEUTICS, INC

3 COLUMBUS CIRCLE, 15TH FLOOR

(Street)

NEW YORK NEW YORK 10019

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/23/2026

3. Issuer Name and Ticker or Trading Symbol
Indaptus Therapeutics, Inc. [ INDP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	11,250,000(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On March 19, 2026, Junyi Dai (the "Reporting Person"), the other purchasers named therein and David Elliot Lazar (the "Seller") entered into a securities purchase agreement pursuant to which the Reporting Person acquired an aggregate of 75,000 shares of the Issuer's Series AAA Convertible Non-Redeemable Preferred Stock (the "Series AAA Preferred Stock"). Each share of Series AAA Preferred Stock is convertible into 150 shares of the Company's common stock, $0.01 par value per share (the "Common Stock"). Following the closing of such transaction which occurred on March 23, 2026, the Reporting Person submitted a notice of conversion with respect to all shares of Series AAA Preferred Stock held by the Reporting Person, resulting in the issuance of an aggregate of 11,250,000 shares of Common Stock.

	/s/ Junyi Dai	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)